WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010149755) 1, 3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/149755    International Application No.:    PCT/EP2010/059029
Publication Date: 29.12.2010 International Filing Date: 24.06.2010
Chapter 2 Demand Filed:    24.03.2011    
IPC:
C07D 403/04 (2006.01), C07D 403/14 (2006.01), C07D 407/14 (2006.01), C07D 409/14 (2006.01), C07D 417/14 (2006.01), A61K 31/4178 (2006.01), A61P 35/00 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basel (CH) (For All Designated States Except US).
BOCK, Mark G. [US/US]; (US) (For US Only).
GAUL, Christoph [DE/CH]; (CH) (For US Only).
GUMMADI, Venkateshwar Rao [IN/IN]; (IN) (For US Only).
SENGUPTA, Saumitra [IN/IN]; (IN) (For US Only)
Inventors: BOCK, Mark G.; (US).
GAUL, Christoph; (CH).
GUMMADI, Venkateshwar Rao; (IN).
SENGUPTA, Saumitra; (IN)
Agent: STRANG, Andrea; NOVARTIS PHARMA AG Patent Department CH-4002 Basel (CH).
DYER, James; Novartis Pharma AG Patent Department CH-4002 Basel (CH)
Priority Data:
1500/CHE/2009 26.06.2009 IN
2181/DEL/2009 21.10.2009 IN
Title (EN) 1, 3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17
(FR) DÉRIVÉS D'IMIDAZOLIDIN-2-ONE 1,3-DISUBSTITUÉS EN TANT QU'INHIBITEURS DE CYP 17
Abstract: front page image
(EN)The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.
(FR)La présente invention concerne des composés de formule (I) et (II), ou un de leurs sels pharmaceutiquement acceptables, dans lesquelles R53, R54, p, q et n sont tels que définis dans le présent document. Il a été découvert que les composés de la présente invention sont utiles en tant qu'inhibiteurs de 17α-hydroxylase/C17,20-lyase.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)